内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

NEJM新闻：快讯！每周一次GLP-1RAs，治疗2型糖尿病

2015-12-08 catxa2016译 MedSci原创

糖尿病GLP-1
关注

Annals of Internal Medicine发表网状Meta分析显示，GLP-1RAs（ glucagon-like peptide-1 receptor agonists，胰高血糖素样蛋白-1受体激动剂）度拉糖肽（Dulaglutide）、艾塞那肽（Exenatide）和他司鲁泰（Taspoglutide）可以最大程度降低糖尿病患者HbA1c（hemoglobin A1c，糖化血红蛋白

《内科医学年鉴》发表网状Meta分析显示，GLP-1RAs（ glucagon-like peptide-1 receptor agonists，胰高血糖素样蛋白-1受体激动剂）度拉糖肽（Dulaglutide）、艾塞那肽（Exenatide）和他司鲁泰（Taspoglutide）可以最大程度降低糖尿病患者HbA1c水平。（FDA尚未批准他司鲁泰用于临床）。

研究人员分析了34个随机试验的结果，比较超过20000名2型糖尿病患者每周注射GLP-1RAs与不使用GLP-1RAs的效果。

结果表明，相对于安慰剂组（1.4%），度拉糖肽1.5mg降低HbA1c的程度最大。其次是每周一次艾塞那肽、度拉糖肽0.75mg和他司鲁泰。受试者体重减少程度最大的是他司鲁泰（1.3kg），其次是艾塞那肽和度拉糖肽。使用度拉糖肽和艾塞那肽的受试者发生症状性低血糖症的风险最高。

每周一次艾塞那肽和度拉糖肽1.5mg与同一制造商的药物做安慰剂相比较，可有效减少利益冲突导致的偏倚。

研究结论：因为Meta分析所使用的证据可靠性较低，认为药物之间存在差异，包括药物排名可以受到质疑。

每周一次艾塞那肽和度拉糖肽可以最大程度降低HbA1c水平，同时不明显减轻体重。

相关链接:

Francesco Zaccardi, Zin Htike, David R Webb, et all. Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis. Ann Intern Med. Published online 8 December 2015.

Victor M Montori, Rene Rodriguez-Gutierrez. The Triumph of Innovation and the Hard Work of Caring for Patients With Diabetes. Ann Intern Med. Published online 8 December 2015.


原文出处：

Kelly Young. Weekly GLP-1RAs Compared for Type2 Diabetes. NEJM Journal Watch. December 8,2015.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1658657, encodeId=894d165865eec, content=<a href='/topic/show?id=4b4d80e878' target=_blank style='color:#2F92EE;'>#GLP-1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8078, encryptionId=4b4d80e878, topicName=GLP-1R)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fea024898996, createdName=360611848, createdTime=Sun Jun 05 22:02:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60542, encodeId=5a576054265, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60544, encodeId=2e096054485, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60545, encodeId=97526054594, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60546, encodeId=78f86054657, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56759, encodeId=835356e591c, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56760, encodeId=fddb56e6011, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56761, encodeId=200f56e6148, content=好消息，, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56762, encodeId=fc5756e628e, content=好消息，, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56763, encodeId=b06c56e63ae, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=)]
    2016-06-05 360611848

    #GLP-1R#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1658657, encodeId=894d165865eec, content=<a href='/topic/show?id=4b4d80e878' target=_blank style='color:#2F92EE;'>#GLP-1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8078, encryptionId=4b4d80e878, topicName=GLP-1R)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fea024898996, createdName=360611848, createdTime=Sun Jun 05 22:02:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60542, encodeId=5a576054265, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60544, encodeId=2e096054485, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60545, encodeId=97526054594, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60546, encodeId=78f86054657, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56759, encodeId=835356e591c, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56760, encodeId=fddb56e6011, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56761, encodeId=200f56e6148, content=好消息，, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56762, encodeId=fc5756e628e, content=好消息，, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56763, encodeId=b06c56e63ae, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=)]
    2016-01-27 doctording1

    不错，赞一个

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1658657, encodeId=894d165865eec, content=<a href='/topic/show?id=4b4d80e878' target=_blank style='color:#2F92EE;'>#GLP-1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8078, encryptionId=4b4d80e878, topicName=GLP-1R)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fea024898996, createdName=360611848, createdTime=Sun Jun 05 22:02:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60542, encodeId=5a576054265, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60544, encodeId=2e096054485, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60545, encodeId=97526054594, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60546, encodeId=78f86054657, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56759, encodeId=835356e591c, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56760, encodeId=fddb56e6011, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56761, encodeId=200f56e6148, content=好消息，, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56762, encodeId=fc5756e628e, content=好消息，, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56763, encodeId=b06c56e63ae, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=)]
    2016-01-27 doctording1

    这篇文章有一定深度

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1658657, encodeId=894d165865eec, content=<a href='/topic/show?id=4b4d80e878' target=_blank style='color:#2F92EE;'>#GLP-1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8078, encryptionId=4b4d80e878, topicName=GLP-1R)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fea024898996, createdName=360611848, createdTime=Sun Jun 05 22:02:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60542, encodeId=5a576054265, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60544, encodeId=2e096054485, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60545, encodeId=97526054594, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60546, encodeId=78f86054657, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56759, encodeId=835356e591c, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56760, encodeId=fddb56e6011, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56761, encodeId=200f56e6148, content=好消息，, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56762, encodeId=fc5756e628e, content=好消息，, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56763, encodeId=b06c56e63ae, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=)]
    2016-01-27 doctording1

    是一篇不错的文章

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1658657, encodeId=894d165865eec, content=<a href='/topic/show?id=4b4d80e878' target=_blank style='color:#2F92EE;'>#GLP-1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8078, encryptionId=4b4d80e878, topicName=GLP-1R)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fea024898996, createdName=360611848, createdTime=Sun Jun 05 22:02:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60542, encodeId=5a576054265, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60544, encodeId=2e096054485, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60545, encodeId=97526054594, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60546, encodeId=78f86054657, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56759, encodeId=835356e591c, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56760, encodeId=fddb56e6011, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56761, encodeId=200f56e6148, content=好消息，, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56762, encodeId=fc5756e628e, content=好消息，, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56763, encodeId=b06c56e63ae, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=)]
    2016-01-27 doctording1

    值得进一步关注

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1658657, encodeId=894d165865eec, content=<a href='/topic/show?id=4b4d80e878' target=_blank style='color:#2F92EE;'>#GLP-1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8078, encryptionId=4b4d80e878, topicName=GLP-1R)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fea024898996, createdName=360611848, createdTime=Sun Jun 05 22:02:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60542, encodeId=5a576054265, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60544, encodeId=2e096054485, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60545, encodeId=97526054594, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60546, encodeId=78f86054657, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56759, encodeId=835356e591c, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56760, encodeId=fddb56e6011, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56761, encodeId=200f56e6148, content=好消息，, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56762, encodeId=fc5756e628e, content=好消息，, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56763, encodeId=b06c56e63ae, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=)]
    2016-01-13 medsic

    good

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1658657, encodeId=894d165865eec, content=<a href='/topic/show?id=4b4d80e878' target=_blank style='color:#2F92EE;'>#GLP-1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8078, encryptionId=4b4d80e878, topicName=GLP-1R)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fea024898996, createdName=360611848, createdTime=Sun Jun 05 22:02:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60542, encodeId=5a576054265, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60544, encodeId=2e096054485, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60545, encodeId=97526054594, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60546, encodeId=78f86054657, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56759, encodeId=835356e591c, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56760, encodeId=fddb56e6011, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56761, encodeId=200f56e6148, content=好消息，, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56762, encodeId=fc5756e628e, content=好消息，, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56763, encodeId=b06c56e63ae, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=)]
    2016-01-13 medsic

    good

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1658657, encodeId=894d165865eec, content=<a href='/topic/show?id=4b4d80e878' target=_blank style='color:#2F92EE;'>#GLP-1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8078, encryptionId=4b4d80e878, topicName=GLP-1R)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fea024898996, createdName=360611848, createdTime=Sun Jun 05 22:02:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60542, encodeId=5a576054265, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60544, encodeId=2e096054485, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60545, encodeId=97526054594, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60546, encodeId=78f86054657, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56759, encodeId=835356e591c, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56760, encodeId=fddb56e6011, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56761, encodeId=200f56e6148, content=好消息，, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56762, encodeId=fc5756e628e, content=好消息，, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56763, encodeId=b06c56e63ae, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=)]
    2016-01-13 medsic

    好消息，

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1658657, encodeId=894d165865eec, content=<a href='/topic/show?id=4b4d80e878' target=_blank style='color:#2F92EE;'>#GLP-1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8078, encryptionId=4b4d80e878, topicName=GLP-1R)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fea024898996, createdName=360611848, createdTime=Sun Jun 05 22:02:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60542, encodeId=5a576054265, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60544, encodeId=2e096054485, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60545, encodeId=97526054594, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60546, encodeId=78f86054657, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56759, encodeId=835356e591c, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56760, encodeId=fddb56e6011, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56761, encodeId=200f56e6148, content=好消息，, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56762, encodeId=fc5756e628e, content=好消息，, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56763, encodeId=b06c56e63ae, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=)]
    2016-01-13 medsic

    好消息，

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1658657, encodeId=894d165865eec, content=<a href='/topic/show?id=4b4d80e878' target=_blank style='color:#2F92EE;'>#GLP-1R#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8078, encryptionId=4b4d80e878, topicName=GLP-1R)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fea024898996, createdName=360611848, createdTime=Sun Jun 05 22:02:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60542, encodeId=5a576054265, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60544, encodeId=2e096054485, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60545, encodeId=97526054594, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60546, encodeId=78f86054657, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 12:23:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56759, encodeId=835356e591c, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56760, encodeId=fddb56e6011, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56761, encodeId=200f56e6148, content=好消息，, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56762, encodeId=fc5756e628e, content=好消息，, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56763, encodeId=b06c56e63ae, content=感谢分享～～, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 11:15:00 CST 2016, time=2016-01-13, status=1, ipAttribution=)]
    2016-01-13 medsic

    感谢分享～～

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

阿布扎比会议呼吁关注糖尿病相关骨病变

糖尿病是普遍存在的慢性疾病,在中东地区是一个越来越重要的公共卫生问题。治疗糖尿病的医生常常不认识糖尿病的并发症——脆性骨折。为了应对该地区急剧增加的脆弱性骨折和2型糖尿病(T2DM)患者，在阿布扎比举行的第三届中东和非洲骨质疏松症会议上，将糖尿病和脆性骨折的关系作为重中之重。先前有关糖尿病和骨质疏松症的工作会议，专家汇报了糖尿病相关骨疾病的流行病学、病理生理学、和管理等最新信息。此外还汇报了来自伊

研究表明：糖尿病患者的牙齿脱落几率比正常人高2倍

· 2015-12-04

-->

FDA警告：糖尿病治疗新秀“SGLT2抑制剂”导致酮症酸中毒风险

近年来,钠-葡萄糖2型转运体(SGLT2)作为一个治疗糖尿病的新靶点受到广泛关注。SGLT2是一类特异性分布在肾脏近曲小管S1段的葡萄糖转运体,其生理功能是负责约90%葡萄糖的重吸收。SGLT2抑制剂通过抑制SGLT2,从而减少肾脏对葡萄糖的重吸收,增加尿糖排出,降低血糖。近期FDA更新SGLT2抑制剂标签，强调该药物酮症酸中毒和严重的尿路感染风险，这两种疾病均会导致住院治疗。2015年5月，FD

Circulation：2-型糖尿病患者中，女性比男性更容易出现心血管疾病！

在以往的研究中，人们已经发现糖尿病患者患心血管疾病风险相对于常人较高，但美国心脏病协会最近发表的一份新的研究报告称，在2-型糖尿病患者中女性相对于男性更容易出现心血管疾病。

NICE：2015年12月2型糖尿病管理指南更新6大要点

NICE：2015年2型糖尿病更新指南6大要点。指南强调，将2型糖尿病患者的个体化治疗方案作为2型糖尿病管理的中心是至关重要的。例如指南建议2型糖尿病成年患者应参与决定个人HbA1c管理目标，HbA1c是反应2-3个月内血液中葡萄糖平均水平的指标。健康专家也建议个体化推荐碳水化合物摄入量、酒精摄入量和进餐模式。所有这些建议可改善2型糖尿病成年患者的预后，减少并发症，提高健康质量。

Am J Epidemiol：常喝咖啡能减少2型糖尿病风险，降低全因死亡

http://www.medicalnewstoday.com/articles/303548.php